Literature DB >> 6335382

Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with alpha-interferon against herpes simplex virus type 2 in mice.

E B Fraser-Smith, D A Eppstein, Y V Marsh, T R Matthews.   

Abstract

The acyclic nucleoside DHPG [9-(1,3-dihydroxy-2-propoxymethyl)guanine] and recombinant human alpha-interferon of clones A/D potentiate each other's antiviral activity against a systemic infection with herpes simplex virus type 2. The effective dose at which 50% of the mice survived was lowered approximately 10-fold for DHPG when it was given in combination with a marginally effective dose of alpha-interferon and greater than 10-fold for alpha-interferon when it was given in combination with a nontherapeutic dose of DHPG.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6335382      PMCID： PMC180056          DOI： 10.1128/AAC.26.6.937

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Specific molecular activities of recombinant and hybrid leukocyte interferons.

Authors:  E Rehberg; B Kelder; E G Hoal; S Pestka
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

2.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

3.  Cell and virus sensitivity studies with recombinant human alpha interferons.

Authors:  M J Kramer; R Dennin; C Kramer; G Jones; E Connell; N Rolon; A Gruarin; R Kale; P W Trown
Journal:  J Interferon Res       Date:  1983

4.  Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in mice.

Authors:  E B Fraser-Smith; D A Eppstein; Y V Marsh; T R Matthews
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

5.  Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2.

Authors:  T L Stanwick; R F Schinazi; D E Campbell; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

6.  Inhibition of human herpesviruses by combination of acyclovir and human leukocyte interferon.

Authors:  M J Levin; P L Leary
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

7.  Combined interaction of antiherpes substances and interferon beta on the multiplication of herpes simplex virus.

Authors:  C Janz; R Wigand
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

8.  Importance of treatment regimen of interferon as an antitumor agent.

Authors:  S H Lee; H Chiu; E Rinderknecht; W Sabo; N Stebbing
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

9.  Potent synergistic inhibition of herpes simplex virus-2 by 9-[(1, 3-dihydroxy-2-propoxy)methyl]guanine in combination with recombinant interferons.

Authors:  D A Eppstein; Y V Marsh
Journal:  Biochem Biophys Res Commun       Date:  1984-04-16       Impact factor: 3.575
  9 in total
  4 in total

Review 1.  Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections.

Authors:  D Faulds; R C Heel
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

2.  Xylotubercidin against herpes simplex virus type 2 in mice.

Authors:  E De Clercq; M J Robins
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

3.  Synergistic activity of combinations of recombinant human alpha interferon and acyclovir, administered concomitantly and in sequence, against a lethal herpes simplex virus type 1 infection in mice.

Authors:  E V Connell; R L Cerruti; P W Trown
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

4.  Acyclonucleosides: Part 2. diseco-Nucleosides.

Authors:  E S H El Ashry; Y El Kilany
Journal:  Adv Heterocycl Chem       Date:  2008-02-28       Impact factor: 3.552
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.